Dudediligence.

C4 Therapeutics, Inc

CCCCNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$2,469,618

6 notices · 231,483 sh

Oct 2025 to Oct 2026

Reported ·

$22,200

1 sale · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

The one reported sale does not carry the 10b5-1 box. It is under 0.01% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-08-14: Mark Mossler, Form 1442026-08-14: JAY GELDMACHER, Form 1442026-08-13: Mark Mossler, Form 1442026-08-12: Mark Mossler, Form 1442026-05-27: Mark Mossler, Form 1442026-03-09: JOLIE M SIEGEL, Form 1442026-01-16: REYNO LEONARD, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-08-14Mark Mossler, Chief Accounting Officer$17,605
4,139 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-14JAY GELDMACHER, Former REZI CEO$1,899,926
82,563 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-13Mark Mossler, Chief Accounting Officer$61,073
15,000 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-12Mark Mossler, Chief Accounting Officer$76,680
19,519 shno plan dateForm 4s on file end Jun 23144 ↗
2026-05-27Mark Mossler, Chief Accounting Officer$35,485
9,087 shno plan dateForm 4s on file end Jun 23144 ↗
2026-03-09JOLIE M SIEGEL, Chief Legal Officer$378,849
101,175 shno plan dateno Form 4 on file144 ↗